Abstract | BACKGROUND AND OBJECTIVE: PATIENTS AND METHODS: Prospective, randomized, double-blind, sham-controlled pilot trial. Patients were randomized to SDM laser treatment (group 1) or sham procedure (group 2). Primary outcome measure was change in best corrected visual acuity (BCVA); secondary outcome was central macular thickness after 3 months. Laser treatment was performed along the detached area. At the 3-month visit, all patients were evaluated for re-treatment if they met re-treatment criteria. RESULTS: Fifteen patients were included in this study: five patients in the sham group and 10 in the treatment group. At 3 months, BCVA was significantly enhanced in the treatment group (P = .006) compared with the sham group ( P = .498). All patients from the sham group needed treatment after 3 months. An improvement in central macular thickness and leakage on fluorescein angiography was noted in all treated patients (in both groups). CONCLUSION: In this limited-size, short-term exploratory study, SDM laser was effective in treating chronic CSC. There was no evidence of retinal damage induced by treatment.
|
Authors | Luiz Roisman, Fernanda Pedreira Magalhães, Daniel Lavinsky, Nilva Moraes, Flávio E Hirai, José Augusto Cardillo, Michel Eid Farah |
Journal | Ophthalmic surgery, lasers & imaging retina
(Ophthalmic Surg Lasers Imaging Retina)
2013 Sep-Oct
Vol. 44
Issue 5
Pg. 465-70
ISSN: 2325-8179 [Electronic] United States |
PMID | 24044709
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright 2013, SLACK Incorporated. |
Topics |
- Adult
- Central Serous Chorioretinopathy
(surgery)
- Chronic Disease
- Double-Blind Method
- Female
- Humans
- Laser Coagulation
(methods)
- Lasers, Semiconductor
- Male
- Middle Aged
- Pilot Projects
- Prospective Studies
- Visual Acuity
|